Cargando…

Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products

BACKGROUND: BAY 81–8973 (Kovaltry) is an unmodified full-length recombinant factor VIII (rFVIII) for treatment of hemophilia A. The BAY 81–8973 manufacturing process results in a product of enhanced purity with a consistently high degree of branching and sialylation of N-linked glycans. This study e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teare, John M, Kates, David S, Shah, Anita, Garger, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435118/ https://www.ncbi.nlm.nih.gov/pubmed/30962676 http://dx.doi.org/10.2147/DDDT.S188171

Ejemplares similares

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
por: Kenet, Gili, et al.
Publicado: (2023)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
por: Traets, Marissa J.M., et al.
Publicado: (2020)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
por: Shah, Anita, et al.
Publicado: (2016)

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
por: Yang, Renchi, et al.
Publicado: (2019)

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
por: Kavakli, K, et al.
Publicado: (2015)

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
por: Ljung, Rolf, et al.
Publicado: (2023)

Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII
por: Swiech, Kamilla, et al.
Publicado: (2011)

Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
por: Chang, Chia-Yau, et al.
Publicado: (2023)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
por: Pocoski, Jennifer, et al.
Publicado: (2016)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS
por: Santoro, Cristina, et al.
Publicado: (2022)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A
por: Tiede, Andreas, et al.
Publicado: (2019)

Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting
por: Chen, Rong, et al.
Publicado: (2022)

The Analysis of Sialylation, N-Glycan Branching, and Expression of O-Glycans in Seminal Plasma of Infertile Men
por: Kratz, Ewa M., et al.
Publicado: (2015)

Determination of major sialylated N-glycans and identification of branched sialylated N-glycans that dynamically change their content during development in the mouse cerebral cortex
por: Torii, Tomohiro, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
por: Bullement, Ash, et al.
Publicado: (2021)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Corrigendum to “The Analysis of Sialylation, N-Glycan Branching, and Expression of O-Glycans in Seminal Plasma of Infertile Men”
por: Kratz, Ewa M., et al.
Publicado: (2015)

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany
por: Olivieri, Martin, et al.
Publicado: (2020)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis
por: O’Hara, Jamie, et al.
Publicado: (2021)

How Full-Length FVIII Benefits from Its Heterogeneity – Insights into the Role of the B-Domain
por: Anzengruber, Julia, et al.
Publicado: (2019)

Natural and Synthetic Sialylated Glycan Microarrays and Their Applications
por: McQuillan, Alyssa M., et al.
Publicado: (2019)

Antibodies Against Unusual Forms of Sialylated Glycans
por: Obukhova, P. S., et al.
Publicado: (2022)

Separation of Sialylated Glycan Isomers by Differential Mobility Spectrometry
por: Lane, Catherine S., et al.
Publicado: (2019)

Sialylation of N-glycans: mechanism, cellular compartmentalization and function
por: Bhide, Gaurang P., et al.
Publicado: (2016)

Cellular and Molecular Engineering of Glycan Sialylation in Heterologous Systems
por: Hombu, Ryoma, et al.
Publicado: (2021)

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation
por: Swystun, Laura L, et al.
Publicado: (2023)

Impact of Fc N-glycan sialylation on IgG structure
por: Zhang, Zhongqi, et al.
Publicado: (2019)

Role of sialylated glycans on bovine lactoferrin against influenza virus
por: Wang, Xilong, et al.
Publicado: (2021)

Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients
por: Pochechueva, Tatiana, et al.
Publicado: (2016)

SabA Is the H. pylori Hemagglutinin and Is Polymorphic in Binding to Sialylated Glycans
por: Aspholm, Marina, et al.
Publicado: (2006)

Green algae Chlamydomonas reinhardtii possess endogenous sialylated N-glycans
por: Mamedov, Tarlan, et al.
Publicado: (2011)

Sialoglycovirology of Lectins: Sialyl Glycan Binding of Enveloped and Non-enveloped Viruses
por: Sriwilaijaroen, Nongluk, et al.
Publicado: (2020)

Gut Microbial Sialidases and Their Role in the Metabolism of Human Milk Sialylated Glycans
por: Muñoz-Provencio, Diego, et al.
Publicado: (2023)

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy
por: Yu, Yingyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_228ckt9e1e7rkrsa2hg1dd98nc